GI CANCERS

October 9th 2024

The sponsor is preparing a phase 2 study to evaluate namodenoson in this patient population.

October 4th 2024

The noninvasive test provides a beneficial screening tool for patients 45 and older at average risk for colorectal cancer.

October 3rd 2024

In an interview with Targeted Oncology, Jeffrey Wong, MD, discussed the potential and future directions of Cu 64 anti-CEA M5A as a PET imaging agent for advanced rectal cancer.

September 26th 2024

The FDA’s Oncologic Drug Advisory Committee voted against the use of checkpoint inhibitors in esophageal cancer with PD-L1 expression less than 1.